Stock Scorer

Assembly Biosciences, Inc. (ASMB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 15M 30M 45M Q4 '19: 4.8M Q1 '20: 4.1M Q2 '20: 39.4M Q3 '20: 34.6M Q4 '20: 1M Q3 '21: 6.3M Q4 '21: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 7.2M Q1 '24: 5.8M Q2 '24: 8.5M Q3 '24: 6.8M Q4 '24: 7.4M Q1 '25: 9.4M Q2 '25: 9.6M Q3 '25: 10.8M Q1 '26: 8.2M Q2 '26: 13.4M Q1 '20 Q4 '20 Q1 '23 Q4 '23 Q3 '24 Q2 '25 Q2 '26

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -18.9M Q4 '21: -62.9M Q1 '22: -23.2M Q2 '22: -24.6M Q3 '22: -23.4M Q4 '22: -23M Q1 '23: -19.6M Q2 '23: -17.5M Q3 '23: -15M Q4 '23: -12.6M Q1 '24: -10.7M Q2 '24: -12.2M Q3 '24: -11M Q4 '24: -11.5M Q1 '25: -9.9M Q2 '25: -11.1M Q3 '25: -10.9M Q4 '25: 19.8M Q1 '26: -11.4M Q2 '26: -6.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -18.8M Q4 '21: -60.3M Q1 '22: -23.1M Q2 '22: -24.5M Q3 '22: -23.1M Q4 '22: -22.4M Q1 '23: -18.9M Q2 '23: -16.9M Q3 '23: -14.4M Q4 '23: -11M Q1 '24: -9.1M Q2 '24: -11.2M Q3 '24: -9.6M Q4 '24: -10.3M Q1 '25: -8.8M Q2 '25: -10.2M Q3 '25: -9.2M Q4 '25: 22.1M Q1 '26: -9.1M Q2 '26: -3.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q2 '21: -21.8M Q3 '21: -18.9M Q4 '21: -19.4M Q1 '22: -27.5M Q2 '22: -17.9M Q3 '22: -19.8M Q4 '22: -19.3M Q1 '23: -23.4M Q2 '23: -13.6M Q3 '23: -13.8M Q1 '24: -18.4M Q2 '24: -17.1M Q3 '24: -15.2M Q4 '24: -407K Q1 '25: -23.4M Q2 '25: -16.8M Q3 '25: -15.1M Q4 '25: 14.2M Q1 '26: -22.1M Q2 '26: -15.5M Q3 '21 Q2 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-30M -20M -10M 0 10M 20M 30M Q2 '21: -21.8M Q3 '21: -18.9M Q4 '21: -19.4M Q1 '22: -27.5M Q2 '22: -17.9M Q3 '22: -19.9M Q4 '22: -19.3M Q1 '23: -23.4M Q2 '23: -13.7M Q3 '23: -14M Q1 '24: -18.4M Q2 '24: -17.1M Q3 '24: -15.2M Q4 '24: -407K Q1 '25: -23.4M Q2 '25: -16.8M Q3 '25: -15.2M Q4 '25: 14.2M Q1 '26: -22.1M Q2 '26: -15.5M Q3 '21 Q2 '22 Q1 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15B 30B 45B Q2 '19: 25.7M Q3 '19: 25.9M Q1 '20: 35.1B Q2 '20: 37.3M Q2 '21: 42.9M Q3 '21: 45.6M Q1 '22: 48.1M Q2 '22: 48.3M Q3 '22: 48.4M Q1 '23: 4.3M Q2 '23: 4.4M Q3 '23: 4.4M Q1 '24: 5.5M Q2 '24: 5.6M Q3 '24: 6.4M Q1 '25: 7.5M Q2 '25: 7.7M Q3 '25: 12.7M Q1 '26: 16.9M Q2 '26: 18.9M Q3 '19 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q3 '21: -2.76 Q4 '21: -3.02 Q1 '22: -2.81 Q2 '22: -2.77 Q3 '22: -2.84 Q4 '22: -23.09 Q1 '23: -27.07 Q2 '23: -30.44 Q3 '23: -33.25 Q4 '23: -13.40 Q1 '24: -10.60 Q2 '24: -8.70 Q3 '24: -6.92 Q4 '24: -6.72 Q1 '25: -6.23 Q2 '25: -5.58 Q3 '25: -4.79 Q4 '25: -0.55 Q1 '26: 0.08 Q2 '26: 1.21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ASMB: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.